Clinical trials: Inflammatory Disorder
Ulcerative Colitis
Effects of Carrageenan-Elimination Diet on Ulcerative Colitis Disease Activity
The study hypothesis is that withdrawal of carrageenan will lead to a longer, relapse free interval in patients with ulcerative colitis.
- Trial name
- NCT01065571
- Testing
- carrageenan, dietary intervention with no-carrageenan diet
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- University of Illinois Chicago
Breast Carcinoma, Pain
Prophylactic Topical Agents in Reducing Radiation-Induced Dermatitis in Patients With Non-inflammatory Breast Cancer
This randomized pilot phase II trial studies and compares prophylactic topical agents in reducing radiation-induced dermatitis in patients with non-inflammatory breast cancer or breast cancer in situ.
- Conditions
- Breast Carcinoma, Pain, Radiation-Induced Dermatitis, Stage 0 Breast Cancer
- Trial name
- Curcumin-II (NCT02556632)
- Testing
- Curcumin-based Gel, Dermatologic Complications Management, Laboratory Biomarker Analysis
- Where
- 6 sites in United States
- Volunteers
- 191 people
- Sponsor
- Gary Morrow
Dysphagia, Dysphonia
The Effect of IV NSAID's and Corticosteroids on Dysphasia and Dysphonia Following ASDF
This study is to assess the efficacy of intra-operative intravenous non-steroidal anti-inflammatory drug (Ketorolac) versus intravenous (dexamethasone) administration on dysphagia and dysphonia after anterior cervical discectomy…
- Trial name
- NCT04650893
- Testing
- Intravenous Ketorolac, Intravenous Dexamethasone
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- University of Nebraska
Metabolic Syndrome X, Insulin Resistance
Oral Contraceptives in the Metabolic Syndrome
Oral contraceptives (OCs) are the most widely used method of reversible birth control. However, the long-term cardiovascular safety of the widely used low-dose OCs (ethinyl-estradiol < 50 mcg) is still debated.
- Conditions
- Metabolic Syndrome X, Insulin Resistance, Obesity, Cardiovascular Diseases
- Trial name
- NCT00205504
- Testing
- Ortho Tri Cyclen
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Virginia Commonwealth University
Inflammatory Myelopathies
CNS Growth Factors Release and Changes in the Inflammatory Environment in Response to Electrical Stimulation in Subjects With Inflammatory Myelopathies
This research is being done to see how different amounts of Functional Electrical Stimulation (FES) affect cycling on factors in blood and spinal cord in people with spinal cord inflammation.
- Trial name
- FIRST-STIM (NCT01440452)
- Testing
- FES Cycling, Cycling without FES, Lumbar puncture
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Johns Hopkins University
HIV, Inflammation
PET/CT Imaging Companion Study To ACTG A5314
HIV-infected individuals on antiretroviral therapy (ART) are at increased risk for cardiovascular disease (CVD), likely due to chronically increased inflammation.
- Conditions
- HIV, Inflammation, Atherosclerosis
- Trial name
- PET/CTMTX (NCT02312219)
- Testing
- Folic Acid, Low Dose Methotrexate
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Massachusetts General Hospital
Crohn Disease, Pediatric Crohns Disease
Personalized AZithromycin/metronidAZole Therapy in Pediatric Crohn's Disease (CD)
This is a multi-center, randomized, controlled open-label add-on design trial pilot study to evaluate the efficacy of personalized adjunctive antibiotic (azithromycin + metronidazole) therapy in pediatric subjects with mild to…
- Trial name
- PAZAZ (NCT04186247)
- Testing
- Azithromycin, Metronidazole, Standard of Care
- Where
- 5 sites in United States, Canada and 2 more
- Volunteers
- 13 people
- Sponsor
- University of North Carolina, Chapel Hill
Asthma, Severe Eosinophilic Asthma
A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab
This is a multicentre, randomised, open-label, parallel-group, active-controlled, phase IV study to assess the reduction of daily Symbicort® maintenance to anti-inflammatory reliever treatment only in participants with severe…
- Trial name
- NCT04159519
- Testing
- Symbicort®, Fasenra®, Ventolin®
- Where
- 23 sites in France, Germany and 2 more
- Volunteers
- 170 people
- Sponsor
- AstraZeneca
Acne Vulgaris
A Treatment for Severe Inflammatory Acne Subjects
Demonstrate that a daily treatment regimen of adapalene 0.3%/benzoyl peroxide 2.5% gel + oral Doxycycline 200 mg is effective and safe in severe inflammatory acne with 3 or fewer nodules or cysts (non-nodulocystic) during a…
- Trial name
- NCT02899000
- Testing
- Adapalene 0.3% / benzoyl peroxide 2.5% emulsion gel, Oral doxycycline hyclate
- Where
- United States
- Volunteers
- 186 people
- Sponsor
- Galderma R&D
Crohn's Disease
A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease
The study hypothesis is to establish the safety and tolerability of long-term open-label (OL) CP-690,550 therapy in subjects with Crohn's disease.
- Trial name
- NCT01470599
- Testing
- CP-690,550
- Where
- 75 sites in United States, Australia and 15 more
- Volunteers
- 150 people
- Sponsor
- Pfizer
Spinal Cord Injury, Chronic Inflammation
Impact of Passive Heat on Metabolic, Inflammatory and Vascular Health in Persons With Spinal Cord Injury
SCI results in higher incidence of heart disease and diabetes and heart disease is the most common cause of death. Chronic inflammation, deleterious changes in vascular structure and impaired glucose metabolism are risk factors…
- Conditions
- Spinal Cord Injury, Chronic Inflammation, Glucose Metabolism, Endothelial Function
- Trial name
- SCIPHS (NCT04971408)
- Testing
- passive heat stress, Control
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- VA Office of Research and Development
Crohn's Disease
Phase III Study of D9421-C 9 mg in Patients With Active Crohn's Disease in Japan
The purpose of this study is to evaluate the clinical efficacy of D9421-C 9 mg once daily compared to Mesalazine 1 g three times a day to patients with mild to moderate active Crohn's disease affecting ileum, ileocecal region…
- Trial name
- NCT01514240
- Testing
- D9421-C capsule 3 mg, Mesalazine tablets
- Where
- 25 sites in Japan
- Volunteers
- 123 people
- Sponsor
- AstraZeneca
Colorectal Neoplasms
A Translational Study of Bevacizumab in Participants With Metastatic Colorectal Cancer
This open-label, prospective, single-arm, multicenter study will evaluate the relationship of the markers of inflammation and progression-free survival (PFS) in participants with previously untreated metastatic colorectal cancer.
- Trial name
- ASCENT (NCT01588990)
- Testing
- Oxaliplatin, Capecitabine, Bevacizumab
- Where
- 17 sites in Australia
- Volunteers
- 128 people
- Sponsor
- Hoffmann-La Roche
Crohn Disease, Ulcerative Colitis
National Observational Study On The Use Of Inflectra™ An Infliximab Biosimilar In Real Life
National, prospective, multicentre observational study designed for eligible patients treated with Inflectra. Its objectives are to describe under real conditions of use, the profile of patients treated with Inflectra and the…
- Conditions
- Crohn Disease, Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis
- Trial name
- ReFLECT (NCT02925338)
- Testing
- QOL questionaire
- Where
- 67 sites in France
- Volunteers
- 1,431 people
- Sponsor
- Pfizer
Cataract
Clinical Study of the Efficacy of the Ophthalmic Emulsion PRO-145 for Inflammation and Pain After Phacoemulsification
objective: To evaluate the efficacy of the ophthalmic emulsion PRO-145 in the treatment of inflammation and pain after phacoemulsification.
- Trial name
- PRO-145/III (NCT03693989)
- Testing
- Difluprednate 0.05%, Prednefrin
- Where
- 5 sites in Mexico
- Volunteers
- 178 people
- Sponsor
- Laboratorios Sophia S.A de C.V.
Metabolic Syndrome
Prothrombotic Inflammatory Markers in Women With Metabolic Syndrome - Effect of Atorvastatin
Little is known regarding the association of individual components of the metabolic syndrome (MBS) and prothrombotic, inflammatory and preclinical cardiac structural and functional markers in women with this syndrome.
- Trial name
- PINK (NCT01785615)
- Testing
- Atorvastatin
- Where
- United States
- Volunteers
- 116 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Inflammation, Crohn's Disease
The Effects of Naltrexone on Active Crohn's Disease
It is hypothesized that the opioid antagonist naltrexone will improve inflammation of the bowel and quality of life in subjects with active Crohn's disease compared to placebo.
- Trial name
- LDN (NCT00663117)
- Testing
- Naltrexone-HCl
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Milton S. Hershey Medical Center
Schizophrenia
Treatment of Schizophrenia With L-tetrahydropalmatine (l-THP): a Novel Dopamine Antagonist With Anti-inflammatory and Antiprotozoal Activity
Schizophrenia is a devastating and complex illness, with multiple symptom and behavioral manifestations. Antipsychotic medications are the mainstay of treatment; however, many patients only partially respond to treatment.
- Trial name
- NCT02118610
- Testing
- L-tetrahydropalmatine (30mg), Sugar pill
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- University of Maryland, Baltimore
Feeding; Difficult, Newborn, Growth Failure
Prophylactic Probiotics to Extremely Low Birth Weight Prematures
Mortality and incidence of severe complications is still high among extremely premature infants. Common causes of severe complications in this population are poor nutrition, necrotizing enterocolitis, and severe infections.
- Conditions
- Feeding; Difficult, Newborn, Growth Failure, Necrotizing Enterocolitis, Sepsis
- Trial name
- PROPEL (NCT01603368)
- Testing
- Lactobacillus reuteri
- Where
- 2 sites in Sweden
- Volunteers
- 134 people, healthy volunteers welcome
- Sponsor
- Ostergotland County Council, Sweden
Hereditary Periodic Fevers
Study of Efficacy and Safety of Canakinumab in Patients With Hereditary Periodic Fevers
This study is to determine whether canakinumab is able to induce and maintain a clinically meaningful reduction of disease activity in participants with Hereditary Periodic Fevers (HPF) compared to placebo.
- Trial name
- NCT02059291
- Testing
- Canakinumab
- Where
- 65 sites in United States, Belgium and 14 more
- Volunteers
- 203 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.